Companies consider delaying reimbursement submissions in Australia
This article was originally published in Scrip
Executive Summary
Some 11 companies are now considering delaying submissions to Australia's reimbursement scientific committee, PBAC, after the federal government recently decided to defer listing new medicines on the Pharmaceutical Benefits Scheme, says Medicines Australia, which represents the pharmaceutical industry. The products at risk of delay included oncology, cardiovascular, respiratory, mental health and diabetic medicines.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.